Nykode Therapeutics AS (OSL:NYKD)

Market Cap	806.57M
Revenue (ttm)	73.37M
Net Income (ttm)	-109.89M
Shares Out	326.55M
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	n/a
Dividend	1.00 (41.98%)
Ex-Dividend Date	n/a

Volume	910,720
Average Volume	608,041
Open	2.384
Previous Close	2.382
Day's Range	2.364 - 2.490
52-Week Range	1.440 - 3.150
Beta	1.10
RSI	53.00
Earnings Date	Feb 25, 2026

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 136
• Stock Exchange: Oslo Børs
• Ticker Symbol: NYKD

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial numbers in USD